Skip to main content
Fig. 5 | Diagnostic and Prognostic Research

Fig. 5

From: Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?

Fig. 5

Incremental cost-effectiveness plane of the lifetime benefit-based strategy and the 10-year risk-based treatment strategy for 5% of patients treated with PCSK9-mAbs (a). Additional cost-effectiveness acceptability curves for both strategies separately (b lifetime benefit-based treatment, c 10-year risk-based treatment)

Back to article page

Diagnostic and Prognostic Research

ISSN: 2397-7523

Contact us